<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223896</url>
  </required_header>
  <id_info>
    <org_study_id>67016.02.01/2016</org_study_id>
    <nct_id>NCT03223896</nct_id>
  </id_info>
  <brief_title>Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray</brief_title>
  <acronym>NALPILO</acronym>
  <official_title>Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Health and Welfare, Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute for Health and Welfare, Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group
      B: naloxone max 16 mg/per day. Study duration 8 weeks. No supportive therapy, but brief
      self-help booklet. Primary outcomes: adverse events, adherence and drop out analysis.
      Secondary outcome: gambling expenditure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group
      B: naloxone max 16 mg/per day. Study duration 8 weeks. No supportive therapy, but brief
      self-help booklet. Primary outcomes: adverse events, adherence and drop out analysis.
      Secondary outcome: gambling expenditure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: max 8 mg/per day naloxone nasal spray
Group B: max 16 mg/per day naloxone nasal spray</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Case Report Form</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gambling expenditure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Money</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gambling</condition>
  <condition>Opioid</condition>
  <condition>Naloxone</condition>
  <condition>Spray</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>max 8 mg/per day naloxone nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>max 16 mg/per day naloxone nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone hydrochloride 20mg/ml</intervention_name>
    <description>Nasal spray</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 years old

          -  South Oaks Gambling Scale (SOGS) 5 or over points

          -  possibility to keep a record with phone and send text messages

          -  fluent in Finnish Language

        Exclusion Criteria:

          -  active drug use (specially opioids) current use - drugs screen

          -  nasal abnormality or mucosal irritability

          -  hepatitis c virus, kidney insufficiency

          -  psychosis, unstable mental health, risk suicide (Beck Depression Inventory)

          -  pregnancy and/or breast feeding

          -  persons according to Finnish Medical Law 188/1999 ยง7-10
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannu Alho, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Health and Welfare, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institution for Health and Welfare</name>
      <address>
        <city>Helsinki</city>
        <zip>00271</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Health and Welfare, Finland</investigator_affiliation>
    <investigator_full_name>Hannu Alho</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <keyword>antagonist</keyword>
  <keyword>nasal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gambling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Narcotic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

